We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
IS Pharma | LSE:ISPH | London | Ordinary Share | GB00B2QBY649 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 87.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
03/12/2010 14:05 | Yes Abingworth LLP love us and I believe they ar fairly clued up on pharma cos. I hope they are right this time.... | red ninja | |
03/12/2010 13:38 | Some interesting developments from yesterday's news... | the_hedge | |
29/11/2010 09:23 | Tipped in press as a buy. | nellie1973 | |
14/11/2010 20:29 | Unlike the situations back in 2007 and 2008 when the then Maelor directors issued shares to themselves and fund-providers at unwarranted discounts to the prevailing market price to fund the Acorus and SEPI acquisitions, at least these recent placings haven't repeated such unsavory (to ordinary PIs) actions. These most recent placings have taken place following a period of almost 10 months in which PIs who believed in the company have been able to acquire stock themselves at a decent discount to the 77p and 80p placing prices so I am beginning to think more favourably of the directors and those providing the funds in that perhaps now they are working towards the interests of all shareholders and not just themselves. | gogoneko | |
14/11/2010 13:28 | IS Pharma goes on acquisition trail A pharmaceutical group which specialises in buying, developing and marketing hospital medicines is to go on the acquisition trail after raising £12.5m in a share placing. Chester-based IS Pharma, which is listed on AIM and has a market value of £29.9m, has placed 15.6 million new ordinary shares at 80p each. It follows the £3.6m it raised last month after placing 4.6 million shares with the London-based healthcare investor Abingworth at 77p each. The company also unveiled interim results for the six months to September 30, with pre-tax profits trebling to £1.4m on the back of a 10% increase in sales to £6.5m, and said it would use the cash to cover milestone payments and fund future acquisitions. Chief executive Tim Wright said: "At the time of the recent strategic investment by Abingworth, we were asked by a number of our existing shareholders to give them an opportunity to further invest in IS Pharma. This Placing is in response to these requests and was oversubscribed. "We are delighted that so many of our existing shareholders have supported this fundraising and we are pleased to welcome a number of significant new institutions who have chosen to support IS Pharma at this important stage in the growth of the company." -------------------- | red ninja | |
11/11/2010 00:08 | Bit of early coverage : (It notes that the reported revenues now don't include the high volume, low margin revenues from Isoplex + Volplex). | gogoneko | |
10/11/2010 08:05 | It would seem from the statement that they could have issued more shares and raised even more capital. I would feel that share price will move north today on the back of solid set of results and that the market will love the placing over subscribed IMHO. | dealit | |
10/11/2010 07:31 | Well this news changes the situation significantly for the company....!! Even though a headline 30% dilution looks bad the millstone of the milestone repayments from past acquisitions looks to have gone from the around the neck of the company in one quick swoop, which I'd say is very good news, and that the recent funds were raised at a price very close to recent highs (e.g. for this year) then even better. Going to look a bit closer, but impressed so far. | gogoneko | |
19/10/2010 10:48 | Falling back again! | philo124 | |
13/10/2010 18:49 | Mmm Abingworth seem to be increasing their holding above that of the new shares subscribed for. Doesn't appear to have had much share price impact... | red ninja | |
11/10/2010 16:52 | £2 x 7 = £14 so that is true. I sold at £1.20 or £8.40 in consolidation prices if i recall correctly... | red ninja | |
11/10/2010 16:37 | I don't think so, the best it did was just over £2 briefly. | tackems | |
11/10/2010 15:40 | Not really given that in late 2000,this stock pre the 7:1 subdivision stood at £14.No that's not an error,10 years ago as Maelor,this stock hit 14 quid. | steeplejack | |
06/10/2010 19:53 | i suppose div payment was a condition of the Buy in. we could see a deal before results in December. This touched on 99p in 2009 .. is it too much to expect £1.10ish? | connello | |
06/10/2010 17:31 | If it is a deal lined up then it will probably be one of the directors selling one of their own companies into ISPH as they have already done in the past!! | tackems | |
06/10/2010 08:23 | Just had a look at Abingworth and they look to be a very, very impressive outfit. If Abingworth are prepared to invest at a premium ( after going over the company in great detail) them things must look very good at ISPH. The company now has over £7m cash so I wonder if they have another deal lined up. If they intend to buy I take it that Abingworth know about it. | clogue | |
06/10/2010 07:12 | Well if this RNS doesn't push the price towards a quid,it's hard to know what will. | steeplejack | |
04/10/2010 20:45 | Hi ALL! lONG TERM SUFFERING SHAREHOLDER HERE - OFFICIAL! | philo124 | |
09/9/2010 13:21 | Might explain the rise in the share price | the_hedge | |
09/8/2010 11:40 | Thanks Targa | rastapastamasta | |
09/8/2010 11:10 | rasta - bottomdrawable but not isable... | targatarga | |
09/8/2010 10:56 | Hi all Is this ISAable? TIA rpm | rastapastamasta | |
30/7/2010 19:52 | I notice on iii that there seem to be more sells than buys, but the price seems to be drifting upwards so someone must be accumulating. | red ninja |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions